Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05461170
PHASE2

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Sponsor: Vir Biotechnology, Inc.

View on ClinicalTrials.gov

Summary

This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy

Official title: A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)

Key Details

Gender

All

Age Range

18 Years - 69 Years

Study Type

INTERVENTIONAL

Enrollment

95

Start Date

2022-09-17

Completion Date

2029-08

Last Updated

2025-10-14

Healthy Volunteers

No

Interventions

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection

DRUG

NRTI

NRTI given orally.

Locations (20)

Investigative Site

Sofia, Bulgaria

Investigative Site

Sofia, Bulgaria

Investigative Site

Stara Zagora, Bulgaria

Investigative Site

Clichy, France

Investigative Site

Pessac, France

Investigative Site

Rennes, France

Investigative Site

Toulouse, France

Investigative Site

Frankfurt, Germany

Investigative Site

Hanover, Germany

Investigative Site

Tübingen, Germany

Investigative Site

Milan, Italy

Investigative Site

Pisa, Italy

Investigative Site

Chisinau, Moldova

Investigative Site

Rotterdam, Netherlands

Investigative Site

Auckland, New Zealand

Investigative Site

Bucharest, Romania

Investigative Site

Birmingham, United Kingdom

Investigative Site

London, United Kingdom

Investigative Site

London, United Kingdom

Investigative Site

Manchester, United Kingdom